Endothelial potential of fetal human fetal osteoblast 1.19 cell line

人類胚骨細胞株作為內皮前驅細胞之潛能探討

王稚翔

指導教授 ： 黎耀基 ； 顏伶汝

國立清華大學/生命科學院/生物科技研究所/碩士(2009年)

https://doi.org/10.6843/NTHU.2009.00338

摘要

內皮前驅細胞為一群具有分化為成熟內皮細胞能力之前驅細胞，並促進胚胎及缺氧的組織中新血管的生成。另外，許多研究也指出內皮前驅細胞具有治療心血管疾病之潛力。然而，其治療的應用性則受限於這群細胞的來源稀少，並且內皮前驅細胞之數量及功能更會因年紀或心血管疾病之影響而減少。本實驗探討一已熟知且被普遍使用的人胚成骨細胞株hFOB 1.19作為內皮前驅細胞來源之可能性。實驗結果顯示，透過基質膠的培養，hfoB可形成如血管狀的網狀構造，並開始表現內皮細胞的表面標誌蛋白如CD31、Flk-1、CD144及vWF；在該結構底下，hFOB也具有攝入低密度脂蛋白的能力。證實hFOB的確具有分化成內皮細胞的能力；在雞胚絨毛尿囊膜實驗中，hFOB細胞亦展現增進血管增生的能力。這些結果顯示hFOB細胞具有易於取得，而且具一致性之優點，並可以作為未來研究內皮前驅細胞的模型。

關鍵字

血管新生 ； 內皮前驅細胞 ； 人類胚骨細胞株

並列摘要

The term “Endothelial Progenitor Cell (EPC)” is generally used to describe a cell type that are capable to differentiate into mature endothelial cell and contribute to neo-vascularization in embryo or in ischemic tissues. There have been an increasing number of studies on the role of EPCs as a potential therapeutics agent for vascular disorders. However, the low amounts of EPCs restrict their usefulness, and the number and function of EPCs can be further reduced by age and cardiovascular risk factors. In this study, we hypothesized that a well-studied and commercially available clonal human osteoprogenitor cell line, the fetal osteoblastic 1.19 cell line (hFOB), may have endothelial differentiation potential. We found that hFOB cells are able to differentiate into a tubular network structure and uptake low-density lipoprotein when they are cultured under Matrigel environment. After tube forming, hFOB cells also express the endothelial progenitor cell markers, such as CD31, Flk-1, V-CAM, vWF. Moreover, hFOB cells also increase the vessel number in the chick chorioallantoic membrane ex vivo angiogenesis experiment. Our data suggest that hFOB cells provide for researchers an easily available, homogeneous, and consistent in vitro model for study of human endothelial progenitor cells.

並列關鍵字

angiogenesis ； endothelial progenitor cell ； human fetal osteoblast

參考文獻

1. Asahara, T., & Isner, J. M. (2002). Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res, 11(2), 171-178.

2. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275(5302), 964-967.

3. Assmus, B., Schachinger, V., Teupe, C., Britten, M., Lehmann, R., Dobert, N., et al. (2002). Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation, 106(24), 3009-3017.

4. Chang, C., Yen, M. L., Chen, Y. C., Chien, C. C., Huang, H. I., Bai, C., et al. (2006). Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells, 24(11), 2466-2477.

5. Fadini, G. P., de Kreutzenberg, S. V., Coracina, A., Baesso, I., Agostini, C., Tiengo, A., et al. (2006). Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J, 27(18), 2247-2255.